Print Page    Close Window

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$6.60

 0.02 (0.30%)

High$6.72
Low$6.40
Volume88,195
Market Cap$70,178,077

02/16/18  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $6.60 with a 52 week high of $21.59 and a 52 week low of $6.07.

Gemphire Announces Pricing of $22 Million Public Offering of Common Stock

02/08/18

Read More

Gemphire Announces Proposed Public Offering of Common Stock

02/07/18

Read More

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

01/31/18

Read More


There are currently no events scheduled.